Genetic Technologies Limited

ASX:GTG ISIN:AU000000GTG7

Genetic Technologies was an early pioneer in recognizing important new applications for "non-coding" DNA (DeoxyriboNucleic Acid). The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species. Its three-pronged business strategy includes: 1) the global commercialization of its patents through an active licensing program; 2) the expansion of its dominant commercial genetic testing business in Australia; and, 3) the commercialization of its various research and development projects aimed at generating further intellectual property of global commercial significance. 
 
     

View in Other Languages

News

Australian Market Report of January 7: Optimism over Iron Ore Prices

🕔1/7/2010 9:30:30 AM 12969

Australian stocks ended flat on Wednesday as shares gave up early gains in the afternoon dragged by banks. Miners advanced as investors were optimistic about the iron ore prices. At the close, the benchmark S&P/ASX200 index was up 1.6 points at 4925.9 points, while the broader All Ordinaries index lifted 7.7 points, or 0.15 per cent, to 4947.2 points.

Read Full Article

Genetic Technologies (ASX: GTG) Advise on Progress with Intellectual Property Licensing on Non-coding DNA

🕔1/15/2008 1:19:11 PM 6019

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) wishes to advise of its progress in licensing its core intellectual property pertaining to non-coding DNA.

Read Full Article

Genetic Technologies Limited ASX: GTG - Company Update - Mr Michael Ohanesian, CEO

🕔10/17/2007 2:00:00 PM 5786

Genetic Technologies Limited (ASX: GTG) - Company Update - Mr Michael Ohanesian, CEO; Genetic Technologies Limited (ASX: GTG) present the following audio webcast regarding "Company Update". You may also download this audio webcast to your computer or portable audio player.

Read Full Article

Aegis Equities Research Announce Health and Life Science Review, August 2006

🕔8/15/2006 2:42:55 PM 13905

The August 2006 edition of our Health & Life Science Quarterly Blue Book profiles niche life sciences companies, with a focus on company strategies, key projects and significant milestones.

Read Full Article

Genetic Technologies Expands Paternity Testing Services into China

🕔6/16/2006 4:21:29 PM 6329

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce that it has entered into an agreement with DNA Bioservices Pty. Ltd. to provide paternity testing services to China.

Read Full Article

GENETIC TECHNOLOGIES LIMITED Deciphering the Lingo - Biotechs Forum; ASX: GTG - Dr Mervyn Jacobson, CEO

🕔4/24/2006 3:15:00 PM 6829

GENETIC TECHNOLOGIES LIMITED Deciphering the Lingo - Biotechs Forum; (ASX: GTG) - Dr Mervyn Jacobson, CEO; Boardroomradio is pleased to announce that GENETIC TECHNOLOGIES LIMITED (ASX: GTG) has publis

Read Full Article
###

45,897 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 13) (Last 30 Days: 56) (Since Published: 8428) 

Company Data

    Fax
  • (03) 9417 2987 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 1987/07/30 
  • Homepage
  • www.gtg.com.au/

More News Results

  • 2024/03/26: GTG Secures Short Term Loan Facility with Radium Capital*
  • 2024/03/25: Appointment of CFO & Company Secretary*
  • 2024/03/22: GTG to develop Worlds Most Advanced Comprehensive Risk Test*
  • 2024/03/20: Results of Extraordinary General Meeting*
  • 2024/03/07: Appendix 3Y - Change of Director's Interest Notice*
  • 2024/02/28: GTG to launch U.S. Customer Digital Media Sales Campaign*
  • 2024/02/23: Appendix 4D & Half-year Financial Report - 31 December 2023*
  • 2024/02/20: Notice of Extraordinary General Meeting & Sample Proxy Form*
*refer to company website